Also known as Remicade
Infliximab (INN; trade name Remicade) is a monoclonal antibody against tumour necrosis factor alpha (TNF-α) used to treat autoimmune diseases. Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the USA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere.Source: Wikipedia
Estimated Total Cost: $2995.22 for an average of 28 days supply
Patients are most commonly prescribed infliximab to treat crohn disease, rheumatoid arthritis, ulcerative colitis, and psoriasis.